Bank of New York Mellon Corp trimmed its position in shares of Enzo Biochem, Inc. (NYSE:ENZ) by 5.5% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 153,928 shares of the medical research company’s stock after selling 8,935 shares during the period. Bank of New York Mellon Corp’s holdings in Enzo Biochem were worth $388,000 at the end of the most recent quarter.
Several other hedge funds have also recently added to or reduced their stakes in the company. BlackRock Inc. increased its holdings in shares of Enzo Biochem by 4.1% during the 4th quarter. BlackRock Inc. now owns 3,755,016 shares of the medical research company’s stock worth $9,463,000 after buying an additional 146,250 shares during the last quarter. Strs Ohio increased its holdings in shares of Enzo Biochem by 16.6% during the 4th quarter. Strs Ohio now owns 253,000 shares of the medical research company’s stock worth $637,000 after buying an additional 36,000 shares during the last quarter. Squarepoint Ops LLC boosted its position in Enzo Biochem by 896.7% during the 3rd quarter. Squarepoint Ops LLC now owns 130,462 shares of the medical research company’s stock worth $275,000 after purchasing an additional 117,373 shares during the period. Clear Harbor Asset Management LLC purchased a new stake in Enzo Biochem during the 4th quarter worth $101,000. Finally, AQR Capital Management LLC purchased a new stake in Enzo Biochem during the 3rd quarter worth $80,000. Institutional investors and hedge funds own 60.38% of the company’s stock.
Shares of Enzo Biochem stock opened at $3.46 on Friday. The company has a fifty day moving average price of $3.26 and a 200 day moving average price of $2.64. The company has a current ratio of 2.09, a quick ratio of 1.85 and a debt-to-equity ratio of 0.08. Enzo Biochem, Inc. has a twelve month low of $1.80 and a twelve month high of $4.85. The stock has a market cap of $166.87 million, a price-to-earnings ratio of -8.05 and a beta of 0.89.
Separately, TheStreet raised shares of Enzo Biochem from a “d+” rating to a “c” rating in a research report on Thursday, March 18th.
In other Enzo Biochem news, major shareholder Discovery Fund Lp Harbert sold 444,768 shares of the company’s stock in a transaction dated Tuesday, March 16th. The shares were sold at an average price of $4.71, for a total value of $2,094,857.28. Corporate insiders own 9.40% of the company’s stock.
Enzo Biochem Company Profile
Enzo Biochem, Inc, an integrated diagnostics, clinical lab, and life sciences company, researches, develops, manufactures, and markets diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. It operates through three segments: Products, Clinical Services, and Therapeutics.
Recommended Story: Strike Price
Want to see what other hedge funds are holding ENZ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Enzo Biochem, Inc. (NYSE:ENZ).
Receive News & Ratings for Enzo Biochem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzo Biochem and related companies with MarketBeat.com's FREE daily email newsletter.